drug · small molecule
docetaxel
Phase 2updated 6mo agoby Nanology LLC🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 71 investigational indications.
targets
Tubulin
all catalysts(0)
nothing on the calendar yet
Trials studying docetaxel
- phase2A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
- phase3A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- phase3A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
News(10)
- GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trialA phase 3 trial has linked GSK’s risvutatug rezetecan to a 67% reduction in the risk of disease progression or death, providing evidence that B7-H3-directed antibody-drug conjugates work in relapse…fiercebiotech · 23d ago
- ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ dataAt one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.biopharma_dive · 24d ago
- ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drugBristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its BioNTech-partnered PD-L1xVEGF-A drug are “very promising,” as phase 3 ambitions ram…fiercebiotech · 25d ago
- ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivalsRoche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.fiercebiotech · 26d ago
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1mo ago
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 2mo ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 2mo ago
- Pfizer punts Seagen ADC, further muddying value of the $43B buyoutThe co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…biospace · 2mo ago
- RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancerThe data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…biospace · 2mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that